LU90025I2 - Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R) - Google Patents

Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R)

Info

Publication number
LU90025I2
LU90025I2 LU90025C LU90025C LU90025I2 LU 90025 I2 LU90025 I2 LU 90025I2 LU 90025 C LU90025 C LU 90025C LU 90025 C LU90025 C LU 90025C LU 90025 I2 LU90025 I2 LU 90025I2
Authority
LU
Luxembourg
Prior art keywords
pct
protein
sec
amino acid
acid sequence
Prior art date
Application number
LU90025C
Other languages
English (en)
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of LU90025I2 publication Critical patent/LU90025I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
LU90025C 1989-02-07 1990-02-06 Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R) LU90025I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3903581A DE3903581A1 (de) 1989-02-07 1989-02-07 Gewebs-plasminogenaktivator-derivat

Publications (1)

Publication Number Publication Date
LU90025I2 true LU90025I2 (fr) 1997-04-22

Family

ID=6373566

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90025C LU90025I2 (fr) 1989-02-07 1990-02-06 Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R)

Country Status (29)

Country Link
US (1) US5223256A (fr)
EP (1) EP0382174B1 (fr)
JP (1) JP2559538B2 (fr)
KR (1) KR970008485B1 (fr)
AT (1) ATE126270T1 (fr)
AU (1) AU623228B2 (fr)
CA (1) CA2025900C (fr)
CZ (1) CZ281836B6 (fr)
DD (1) DD291779A5 (fr)
DE (2) DE3903581A1 (fr)
DK (1) DK0382174T3 (fr)
ES (1) ES2031804T3 (fr)
FI (1) FI100244B (fr)
GR (2) GR900300140T1 (fr)
HK (1) HK153396A (fr)
HU (1) HU218092B (fr)
IE (1) IE61077B1 (fr)
IL (1) IL93280A (fr)
LU (1) LU90025I2 (fr)
LV (1) LV10302B (fr)
NL (1) NL970008I2 (fr)
NO (2) NO306563B1 (fr)
NZ (1) NZ232337A (fr)
PT (1) PT93082B (fr)
RU (1) RU2107094C1 (fr)
SK (1) SK55890A3 (fr)
UA (1) UA27111A1 (fr)
WO (1) WO1990009437A1 (fr)
ZA (1) ZA90861B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634007A (en) * 1985-12-02 1987-01-06 Adolph Coors Company Carton blank with perforated tear line
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
DE4123845A1 (de) * 1991-07-18 1993-01-21 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
WO1992018157A1 (fr) * 1991-04-16 1992-10-29 Boehringer Mannheim Gmbh Unite de conditionnement pharmaceutique contenant des activateurs de plasminogene destines a etre administres en plusieurs bols
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (de) * 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5723122A (en) * 1995-06-01 1998-03-03 Boehringer Mannheim Gmbh Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
AU4259496A (en) * 1994-12-06 1996-06-26 Boehringer Mannheim Gmbh Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
BR9811531A (pt) 1997-07-23 2000-08-22 Roche Diagnostics Gmbh Preparação de proteìnas mutadas humanas em células humanas por meio de recombinação homóloga
WO1999009184A1 (fr) * 1997-08-13 1999-02-25 Roche Diagnostics Gmbh Activateur du plasminogene a pouvoir zymogene ameliore et a liaison a la fibrine reduite
AU9162198A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with improved zymogenity
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
RU2323001C1 (ru) * 2007-05-30 2008-04-27 Общество с ограниченной ответственностью "Научно-производственное предприятие "Техноген" Фармацевтическая композиция, обладающая фибринолитическим действием
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
EP2289541A1 (fr) 2009-08-31 2011-03-02 PAION Deutschland GmbH Traitement des troubles neurologiques ou neuro-dégénératifs
EP2289542A1 (fr) 2009-08-31 2011-03-02 PAION Deutschland GmbH Traitement des troubles neurologiques ou neuro-dégénératifs
MX2019009137A (es) 2017-02-03 2019-12-19 Acticor Biotech Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos.
WO2018210860A1 (fr) 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un accident vasculaire ischémique cérébral aigu
EP3806833A1 (fr) 2018-06-15 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de pi3kc2b pour la préservation de l'intégrité d'une barrière cellulaire de l'endothélium vasculaire
WO2021148439A1 (fr) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de stimulation de la fonction cérébrovasculaire
WO2021249974A1 (fr) 2020-06-09 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Particules de polysaccharide fonctionnalisées avec du fucoïdane avec t-pa pour un traitement thrombolytique ciblé
US20250154252A1 (en) 2022-02-21 2025-05-15 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
EP4556492A1 (fr) 2023-11-14 2025-05-21 Acticor Biotech Traitement de maladies cardiovasculaires à l'aide d'anticorps anti-gpvi humain dans des sous-populations de sujets

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
EP0112122B1 (fr) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Activateur de plasminogène
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
US5073494A (en) * 1985-04-22 1991-12-17 Genentech, Inc. Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
DE3611817A1 (de) * 1986-04-08 1987-10-15 Boehringer Mannheim Gmbh Verfahren zur renaturierung von proteinen
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
US4898825A (en) * 1986-05-07 1990-02-06 Mitsui Toatsu Chemicals, Incorporated Methods for purification of single-chain and double-chain tissue plasminogen activator
JPH0779692B2 (ja) * 1986-05-07 1995-08-30 三井東圧化学株式会社 一本鎖ｔ−ＰＡと二本鎖ｔ−ＰＡを分離する方法
JPS6463378A (en) * 1986-08-11 1989-03-09 Mitsui Toatsu Chemicals Separation of single stranded tpa and double standard tpa
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5037752A (en) * 1987-10-09 1991-08-06 Monsanto Company Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277
US4963357A (en) * 1987-10-09 1990-10-16 Monsanto Company Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor

Also Published As

Publication number Publication date
LV10302A (lv) 1994-10-20
DK0382174T3 (da) 1996-01-02
CZ281836B6 (cs) 1997-02-12
LV10302B (en) 1995-04-20
RU2107094C1 (ru) 1998-03-20
ES2031804T3 (es) 1995-11-01
NL970008I2 (nl) 1997-07-01
NO2000002I1 (no) 2000-05-19
DE3903581A1 (de) 1990-08-16
NZ232337A (en) 1991-09-25
GR900300140T1 (en) 1991-09-27
ATE126270T1 (de) 1995-08-15
KR910700336A (ko) 1991-03-14
GR3017099T3 (en) 1995-11-30
UA27111A1 (uk) 2000-02-28
PT93082B (pt) 1996-03-29
SK279029B6 (sk) 1998-05-06
WO1990009437A1 (fr) 1990-08-23
DE59009487D1 (de) 1995-09-14
IL93280A (en) 1995-08-31
FI100244B (fi) 1997-10-31
JPH03500724A (ja) 1991-02-21
EP0382174B1 (fr) 1995-08-09
ZA90861B (en) 1990-11-28
NL970008I1 (nl) 1997-04-01
FI904951A0 (fi) 1990-10-08
KR970008485B1 (ko) 1997-05-24
CA2025900A1 (fr) 1990-08-08
HU901644D0 (en) 1991-04-29
IE61077B1 (en) 1994-09-21
HK153396A (en) 1996-08-16
NO904211D0 (no) 1990-09-27
NO306563B1 (no) 1999-11-22
EP0382174A1 (fr) 1990-08-16
HU218092B (hu) 2000-05-28
IE900343L (en) 1990-08-07
JP2559538B2 (ja) 1996-12-04
US5223256A (en) 1993-06-29
IL93280A0 (en) 1990-11-29
ES2031804T1 (es) 1993-01-01
SK55890A3 (en) 1998-05-06
HUT58813A (en) 1992-03-30
NO904211L (no) 1990-09-27
AU5047090A (en) 1990-09-05
PT93082A (pt) 1990-08-31
AU623228B2 (en) 1992-05-07
CZ55890A3 (en) 1996-10-16
DD291779A5 (de) 1991-07-11
CA2025900C (fr) 1999-01-19

Similar Documents

Publication Publication Date Title
LU90025I2 (fr) Reteplase et ses dérivés pharmaceutiquement acceptables (Rapilysin R)
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
ATE140969T1 (de) Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
ES2009216A6 (es) Metodo de preparar un derivado de interleucina-lalfa.
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ES2009215A6 (es) Procedimiento de preparar un derivado de interleucina-1beta.
ES2108694T3 (es) Inhibidor de proteasa.
ATE93388T1 (de) Paracetamol enthaltende arzneizubereitung.
KR910007963A (ko) pST의 일부분에 대응하는 아미노산 서열을 갖는 펩티드, 그에 대한 항체 및 pST 활성에 효력을 더하는 방법
AU4721185A (en) Protein absorption enhancing agents